STOCK TITAN

Eiger BioPharmaceuticals, Inc. - EIGR STOCK NEWS

Welcome to our dedicated page for Eiger BioPharmaceuticals news (Ticker: EIGR), a resource for investors and traders seeking the latest updates and insights on Eiger BioPharmaceuticals stock.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) is a commercial-stage biopharmaceutical company headquartered at 500 Crescent Ct Ste 300, Dallas, Texas. The company focuses on the development of innovative therapies for rare and ultra-rare diseases.

Recently, Eiger has redirected its efforts towards the development of avexitide for hyperinsulinemic hypoglycemia indications. This includes significant potential in treating post-bariatric hypoglycemia (PBH), where Phase 2 clinical trials have shown promising results, and the FDA has provided alignment on Phase 3 endpoints and study design. Eiger also plans to develop avexitide for congenital hyperinsulinism as a secondary indication.

The company continues to commercialize Zokinvy® (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PDPL). Eiger recently received marketing approval for Zokinvy in Japan through a partnership with AnGes, Inc., further expanding its global reach.

In a strategic move, Eiger is exploring partnering opportunities for its virology assets, including lonafarnib-based regimens for hepatitis delta virus (HDV) and peginterferon lambda. Despite recent challenges, such as the discontinuation of the Phase 3 LIMT-2 study of peginterferon lambda due to safety concerns, Eiger remains committed to its primary goals.

Financially, Eiger reported total revenue of $4.6 million for Q2 2023 and $3.2 million for Q3 2023, indicating a stable financial condition supported by strategic cost reductions and workforce optimization. The company’s cash runway is extended into the fourth quarter of 2024, enhancing its capacity to pursue ongoing projects and strategic initiatives.

As of January 2024, Eiger announced a 1-for-30 reverse stock split to comply with Nasdaq's listing requirements and maintain its market position. The company is also navigating a Chapter 11 bankruptcy process to facilitate an orderly wind down of its operations and the sale of its assets, including a “stalking horse” agreement for Zokinvy.

Dr. David Apelian, with extensive experience in clinical development and regulatory affairs, leads Eiger as its CEO, guiding the company through these transformative times.

For further details and updates, visit the company’s website at www.eigerbio.com.

Rhea-AI Summary

Eiger BioPharmaceuticals reported strong Q1 2021 results with net income of $29.2 million, or $0.85 per share, driven by a one-time gain from the sale of a Priority Review Voucher. Total net revenue reached $3.6 million from Zokinvy sales following its U.S. launch. The company is advancing its Phase 3 D-LIVR study for Lonafarnib, 75% enrolled, and plans to initiate the LIMT-2 study for Lambda therapy. Cash reserves stood at $160.5 million, providing funding into Q4 2023. Operational costs increased, with R&D expenses at $13.8 million, compared to $9.5 million last year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
-
Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq:EIGR) announced the inclusion of Peginterferon Lambda in the Phase 3 TOGETHER study targeting COVID-19 outpatients. The trial will evaluate Lambda's efficacy against emergency room visits and hospitalizations, with a target enrollment of 800 patients at various sites in Brazil and potential expansion to Toronto, Canada. The study aims to address the urgent need for outpatient treatments amid the COVID-19 pandemic. Lambda, an investigational agent, is recognized for its potential to stimulate immune responses and tackle emerging viral variants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq:EIGR) will host a conference call on May 6, 2021, at 4:30 PM ET, to discuss its Q1 2021 financial results and provide a business update. The conference will focus on Eiger's advancements in treatments for rare diseases, including Hepatitis Delta Virus and Hutchinson-Gilford Progeria Syndrome. Notably, Lonafarnib is in a global Phase 3 trial, while Peginterferon lambda is entering Phase 3. Zokinvy is the first FDA-approved product, with a Marketing Authorization Application under review in Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
conferences earnings
Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq:EIGR) announced the appointment of Kim Sablich to its Board of Directors. Ms. Sablich brings over 20 years of pharmaceutical experience, including her role as Executive Vice President at Jazz Pharmaceuticals. Her expertise involves building commercial product portfolios in rare disease programs. Eiger is advancing therapies for Hepatitis Delta Virus and has a strong focus on unmet medical needs. This leadership addition aims to enhance Eiger's strategic insights during the pivotal stages of its product development and commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
management
-
Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq: EIGR) reported its 2020 financial results, revealing a net loss of $65.1 million, or $2.31 per share, compared to $70.3 million, or $3.08 per share, in 2019. As of December 31, 2020, cash and equivalents totaled $128.8 million, up from $95 million a year prior. The company plans to complete enrollment of the Phase 3 D-LIVR study for Lonafarnib in 2021, aiming to provide foundational therapies for Hepatitis Delta Virus. Eiger also plans to initiate the Phase 3 LIMT-2 study for Lambda and commercialize Zokinvy, launched in January 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
-
Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq: EIGR) announced positive results from the Phase 2 PREVENT study of Avexitide for treating severe Post-Bariatric Hypoglycemia (PBH). The study showed statistical significance in increasing mean plasma glucose levels, reducing hypoglycemia events, and lowering peak insulin levels. Both dosing regimens (30 mg BID and 60 mg QD) were effective, with fewer participants needing rescue medications. Well-tolerated, the treatment demonstrated significant improvements in clinical outcomes. Eiger has received FDA and EMA concurrence for a Phase 3 study to further evaluate Avexitide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq:EIGR) announced final results from the Phase 2 ILIAD study of Peginterferon Lambda for COVID-19, published in Lancet Respiratory Medicine. The trial showed that a single dose of Lambda accelerated SARS-CoV2 clearance in outpatients, potentially improving clinical outcomes and reducing virus spread. Among 60 patients, only one in the Lambda group required emergency care. Eiger is finalizing FDA guidance for a potential Phase 2/3 registration study of Lambda in COVID-19, amid concerns over virus variants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.39%
Tags
covid-19
-
Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq:EIGR) has announced the U.S. commercial launch of Zokinvy™ (lonafarnib), the first FDA-approved treatment for Hutchinson-Gilford Progeria Syndrome (HGPS) and processing-deficient progeroid laminopathies. Approved in November 2020, Zokinvy is designed to reduce mortality risk in affected patients. To support patients, Eiger has established Eiger OneCare™, offering personalized assistance and reimbursement support. Approximately 180 eligible patients have been identified, with the company also pursuing international approvals, including an application with the European Medicines Agency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
none
-
Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq:EIGR) reports significant progress in its product pipeline, focusing on Hepatitis Delta Virus (HDV) therapies. Key highlights include the planned completion of Phase 3 D-LIVR study enrollment in 2021 and the initiation of Phase 3 LIMT-2 study for Peginterferon Lambda in HDV later in 2021. The company also plans to launch Zokinvy following its FDA approval for Progeria in January 2021. Financially, Eiger anticipates $176M in cash and equivalents, expected to fund operations through Q4 2023, while selling a Priority Review Voucher for $95M.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.06%
Tags
none
Rhea-AI Summary

Eiger BioPharmaceuticals has received FDA approval for Zokinvy (lonafarnib) to treat Hutchinson-Gilford Progeria Syndrome (HGPS) and processing-deficient Progeroid Laminopathies. This groundbreaking treatment shows a 60% reduction in mortality for Progeria patients, extending survival by an average of 2.5 years. The approval grants a Rare Pediatric Disease Priority Review Voucher to Eiger, which can be sold, with proceeds shared with the Progeria Research Foundation. Eiger also announces the launch of Eiger OneCare™ for patient support and access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags

FAQ

What is the market cap of Eiger BioPharmaceuticals (EIGR)?

The market cap of Eiger BioPharmaceuticals (EIGR) is approximately 2.6M.

What is Eiger BioPharmaceuticals' focus?

Eiger BioPharmaceuticals focuses on developing innovative therapies for rare and ultra-rare diseases.

What are Eiger's lead products?

Eiger's lead products include avexitide for post-bariatric hypoglycemia (PBH) and Zokinvy® (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS).

What recent strategic changes has Eiger made?

Eiger has refocused its efforts on avexitide for hyperinsulinemic hypoglycemia indications and exploring partnerships for its virology assets. The company announced a 1-for-30 reverse stock split and is navigating a Chapter 11 bankruptcy process.

How is Eiger financially performing?

Eiger reported total revenue of $4.6 million for Q2 2023 and $3.2 million for Q3 2023. The company has extended its cash runway into Q4 2024 through strategic cost reductions.

Who is leading Eiger BioPharmaceuticals?

Dr. David Apelian is the CEO of Eiger BioPharmaceuticals, bringing extensive experience in clinical development and regulatory affairs.

What is the significance of the reverse stock split?

The 1-for-30 reverse stock split aims to comply with Nasdaq's minimum bid price requirement and maintain the company's market listing.

What is avexitide used for?

Avexitide is being developed for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI).

What is Zokinvy® (lonafarnib)?

Zokinvy® (lonafarnib) is a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PDPL).

What is the status of Eiger's virology assets?

Eiger is evaluating strategic partnering options for its virology assets, including lonafarnib-based regimens for HDV and peginterferon lambda.

Where can I find more information about Eiger?

For additional information and updates, visit Eiger BioPharmaceuticals' website at www.eigerbio.com.

Eiger BioPharmaceuticals, Inc.

Nasdaq:EIGR

EIGR Rankings

EIGR Stock Data

2.55M
1.27M
11.8%
43.86%
2.27%
Biotechnology
Healthcare
Link
United States
Palo Alto